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ABSTRAK 
Rawatan Nebulizer Gabungan Lignocaine Dan Salbutamol Untuk Penyakit 
Serangan Akut Asma 
PENGENALAN 
Rawatan penyakit asma di Jabatan Kecemasan pada hari ini adalah satu cabaran kepada 
semua doctor pakar kecemasan and juga paramedik-pararnedik. Banyak jenis rawatan 
untuk peyakit asma telah diperkenalkan kebelakangan ini, dan akhir-akhir ini, ubat bius 
pun telah didapati mempunyai ciri-ciri yang boleh memberi keberkesanan dalam rawatan 
penyakit asma. Sebelum ini, didapati ubat bilts mempunyai kebolehan untuk 
mengurangkan kesempitan saluran paru-paru. Ubat bius ini adalah Lignocaine. 
Ubat lignocaine sering digunakan untuk sebagai bius dan juga untuk rawatan jantung. Ia 
mempunyai masa untuk bertindak yang singkat . Selain daripada keberkesanaan untuk 
mengurangkan kesempitan saluran paru-paru, ia juga didapati mempunyai cirri-ciri untuk 
mengurangkan radang. 
OBJEKTIF KAJIAN 
Objektif kajian ini adalah untuk menyelidik keberkesanaan gabungan nebulizer 
lignocaine dengan salbutamol bila dibandingkan dengan rawatan nebulizer salbutamol 
dalam serangan akut asma. Kajian ini inginjuga melihat kesan-kesan sampingan daripada 
rawatan gabungan salbutamol and lignocaine. 
K AIWAH 
Satu kajian prospckti f telah dijalankan ke atas 50 pesakit yang dating ke labman 
Keccmasan dan memcrl ukan rawata ll untuk se rangan aku! 85ma. Pesak it yang m emenuhi 
kriteria akan dipil ih untuk diberi rawatan gabungan nebulizer salbutamo \ denga n 
lignocaine ataupun rawatan nebulizer salbutamol . Sukatan " peak expiratory flow rate "', 
tekanan darah, kadar nadi dan pernafasan, dan saturasi oksigen mcnggunakan pera lata n 
SP02. 
K EPUTUSAN 
Ke putusan daripada 50 pesakit yang memerlukan rawatan nebulizer lin t-uk serangan aku! 
a5ma menunj ukkan gabungan nebuli ze r salbutamol dengan lignocaine mempunyai 
keberkesanaan yang sarna dengan rawatan nebulizer salbutamol. Nilai peratusan kenaikan 
PEFR yang didapati dalam masa 15 minit adalah 20.92 ±28.23 (Salbutamol) an d 18.01 ± 
22.09 (Gabungan), dan nilai p 0.687. Nilai peratusan kenaikan PEFR yang didap ati da larn 
masa 30 minit adalah 33.9 1 ± 34.79 (Salbutamol) and 36.02 ± 41.1 5 (Gabungan) dengan 
nilai p 0.846. Daripada 25 pesaki t yang mendapati rawatan gabungan salbutamol and 
lignocaine, 9 pesakit mengalami rasa kebas di dalam mulut dan 16 pesakit m engalam i 
kedua-dua kebas di mulut dan rasa pahil. 
KESIMPULAN 
Rawatan gabungan nebulizer salbutamol dan lignocaine didapati tidak mempunyal 
kelebihan mengurangkan kesempitan saluran paru-paru untuk pesakit serangan akut asma 
jika dibandingkan dengan rawatan nebulizer salbutamol. Tidak ada kesan-kesan 
sampingan yang baru disebabkan oleh ubat lignocaine telah berlaku. 
ABSTRACT 
Nebulized Combined Lignocaine And Salbutamol In Treatment Of Acute Asthma 
(A Pilot Study) 
INTRODUCTION 
Management of asthma in Emergency. Department remains a challenge to all 
Emergency Physician and Allied Health Personnel. Various modality of treatment has 
surfaced since the last decade and lately, anaestheti~ medications have found a place in 
treatment of mild to moderate asthma patients. Anaesthetic medications have long been 
found to have direct effect on airway smooth muscle and it causes relaxation of the 
bronchial smooth muscles. The anaesthetic medication in question is Lignocaine. 
Lignocaine is an local anaesthetic and anti-arrythmic medication that is easily available. 
It has a rapid onset of action and short duration of action. Lately it has been found to have 
property to attenuate reflex bronchoconstriction and also anti-inflammatory. 
STUDY OBJECTIVE 
The objective of this study is to compare the result of relief of 
bronchoconstrictions in patients with acute asthma when they are given either combined 
nebulized lignocaine & salbutamol or salbutamol only. This study also would like to 
document the side effects of combined nebulized lignocaine and salbutamol. 
METHOD 
A prospective study was conducted on 50 patients who had come to the emergency 
department and required treatment for acute exacerbation of mild to moderate asthma. 
Patients who fulfilled the criterias for inclusion were randomized to receive either plain 
salbutamol or combined salbutamol with lignocaine nebulized treatment. Measurements 
of peak expiratory flow rate and other clinical datas such as blood pressure, pulse rate, 
respiratory rate and oxygen saturation level will be t*en in intervals. 
RESULTS 
The results from 50 patients requiring treatment for acute exacerbation of asthma showed 
that there were no significant difference between those randomized to receive plain 
salbutamol treatment and those receiving combined salbutamol and lignocaine nebulizers. 
At 15 minutes of treatment, the mean percentage of increased PEFR value of 20.92 
±2S.23 (Single) and IS.01 ± 22.09 (Combined) . The p value seen was 0.687 at 15 
minutes interval of treatment. Even at 30 minutes of treatment shows the mean 
percentage value of increased PEFR at 33.91 ± 34.79 (Single) and 36.02 ± 41.15 
(Combined) with p value of 0.846. Out of 25 patients who were given combined 
saJbutamoJ and lignocaine treatment, 16 patients experienced numbness of the oral cavity 
and 9 patients experienced both bitterness taste and numbmess of the oral cavity. 
CONCLUSION 
Combined salbutamol and lignocaine did not have a better relief of bronchoconstriction 
as compared to salbutamol nebulization in mild to moderate asthma. The expected side 
effects of lignocaine were encountered and there were no new ones. 
1. INTRODUCTION 
Management of asthma patients in worldwide emergency department centers 
remains a challenge to all physicians and allied health personnel. Various modalities of 
treatment for this group of patients are available and have proven their efficacy till today, 
but they are not being used without their own side effects. In addition to this, patients 
with acute exacerbation of asthma presents themselves to emergency department in 
various degree of severity, either walking in or brought in unconscious by family 
members. With this, the treatment of asthma patients remains a challenge to any medical 
personnel. 
All emergency departments in Malaysia have specialized section in their 
establishment for the sole treatment of asthma. These group of patients are given the 
"green lane" priority where asthmatic patients will be given treatment first for their 
exacerbation attacks while the doctor in charge of the emergency department attends to 
other cases of higher priority. Usually these asthma bays are manned by allied health 
personnel like staff nurses and medical assistants. Severe asthma cases are not managed 
in asthma bay and are triaged straight to red zone and attended immediately by the doctor 
in-charge. 
2. LITERATURE REVIEW 
Asthma is a chronic disease of the airway which can cause significant morbidity 
to the patient from all age groups if proper therapy is not instituted. In genetically 
predisposed individuals, asthma is a chronic inflammation of the lung airways caused by 
environmental factors. The major symptoms face by these group of patients are episodic 
obstructions in the airway and also presence of reversible bronchial hyperresponsiveness. 
Recent rise in asthma prevalence are due to dramatic changes in industrialized cultures 
(Umetsu el aI., 2002). This causes dysregulation in the T Helper CeJI 2 - biased immune 
response and the overproduction of interleukins. This dysregulation is readily induced in 
the modem environment leading to lung inflammation, airway eosinophilia, increased 
mucous production in the airway and airway hyperactivity. 
Various pharmaceutical companies are striving daily to come out with an anti-
asthmatic drug that is effective, provides instant relief, convenient dosing regime and 
most importantly, at an affordable price and minimal side effects. 
In the Emergency Department, doctors and nurses have been using various types 
of anti-asthmatics. It ranges from the inhaled ~2-agonists (salmeterol and fonnoterol), 
methyl-xantines and anti-cholinergics. Inhaled glucocorticoids like budesonide, 
fluticasone propionate and beclomethasone are the most effective treatment available for 
the control of various degrees of asthma severity (Barnes, 2004). 
2.1 LIGNOCAINE (LIDOCAINE) 
Lately, local anaesthetic agents have been getting attention around the world in 
the treatment of asthma. The particular anaesthetic agent is question is Lignocaine 
(Lidocaine). This local anaesthetic agent is an amino-amide and has fast onset of action 
and short duration of action. Being an amino-amide, it's metabolized in the liver. The 
mechanism of action is blockage of voltage-gated sodium channels in excitable tissue, 
primarily the nerves (Katzung, 2007) It has been used regularly as local anaesthesia of 
the airway in the flexible bronchoscopy procedure in medical centres around the world as 
recommended by the British Thoracic Society (200 I). The total dose of lignocaine 
(lidocaine) should be limited to 8.2 mg/kg in adults (approximately 29 ml of a 2% 
solution for a 70 kg patient) with extra care in the elderly or those with liver or cardiac 
impairment. 
In 1999, lignocaine in both intra-venous and inhalational fonn was used to 
attenuate reflex bronchoconstriction in response to histamine challenge and found that 
both intravenous and inhalationallignocaine provides good results (Groeben et al., 1999). 
The additional key point in this study is that they found the plasma level of lignocaine in 
patients that were given the inhalational way was significantly lower than the intravenous 
route. Therefore, nebulized lignocaine holds a promise to be another bronchodilator agent 
in treating patient with bronchoconstriction episodes. Earlier on, bronchoconstriction can 
also be reduced by lignocaine in exercise induced asthma (Enright et al., 1980). 
Lignocaine has a particular side effect when used alone in the airway as itself can 
provoke bronchoconstriction, seen in Basenji-Greyhound dogs with hyperactive airways 
when they are given lignocaine inhalation and observed high resolution computed 
tomography (Bulut et af., 1996). This property of inhaled lignocaine was easily countered 
when in 2000, combinations of salbutamol, salbutamol and lignocaine combined and a 
placebo for on a histamine challenge via inhalational route. It was noted that salbutamol 
and lignocaine provides good attenuation to the reflex bronchoconstriction (Groeben et 
af., 2000). Some of the patients that were given inhaled lignocaine experienced 
bronchoconstriction, but those on both inhaled salbutamol and lignocaine showed that the 
initial bronchoconstriction can be prevented. In this article it was recommended that the 
combination of salbutamol and lignocaine be used if instrumentation of the airway is 
required to mitigate the bronchoconstriction, 
In 1996, it was incidentally found out from patient who had just undergone 
bronchoscopy, that their bronchoalveolar lavage fluid contains significant high amount 
of lignocaine and that lignocaine potently shortens eosinophil survival (Ohnishi et af., 
1996). It was noted that (i) lignocaine inhibited eosinophil survival by causing apoptosis 
rather than necrosis ; and (ii) the mechanism of cell death was clearly tim.e dependent, 
requiring at 24 hours of exposure to lignocaine (Okada, 1998). Moreover, it is well 
established that lignocaine at high concentrations can also block potassium channels 
(Olschewski et af., 1996). 
This effect is quite similar to those of the glucocorticoids that is being used in the 
treatment of asthma. With this new found property of lignocaine, it was used to perform a 
study on asthma patients whom were on oral glucorticoids. It was noted that those 
patients who were given daily inhaled lignocaine, were able to tail down their 
glucocorticoid dosage over a period of time, and it proves that lignocaine provides 
effective and safe therapy in patients in the mild to moderate category of asthma (Hunt el 
al., 2004). 
There were no other significant side effects being noted other than mild 
bronchoconstriction when lignocaine was used in the above studies, but this was easily 
prevented with addition of salbutamol to the lignocaine being nebulized. Furthennore, 
inhalational route of lignocaine provides adequate attenuation response of histamine-
induced bronchoconstriction and were found that the serum levels of lignocaine were of 
safe level. 
Intravenous lignocaine has profound effects on intracellular calcium level in 
smooth muscle. It causes relaxation of the smooth muscle by reducing the intracellular 
calcium level (Kai et al., 1993). This local anaesthetic also causes inhibiton of neurally 
mediated acetylcholine release (Brown et al., 2001), and therefore its use in asthma 
during anaesthesia is acceptable (Yamakage, 2002). 
From the above studies, lignocaine proves to be promising bronchodilator drug as 
it can provide good attenuation of bronchoconstriction and mimics the effect of 
corticosteroid effects on the airway. Apart from this two primary actions, it is also noted 
that inhaled lignocaine provides good response when given to patients with intractable 
cough (Udezue, 2001). 
3. OBJECTIVES 
3.1 GENERAL OBJECTIVES 
3.1.1 To compare the result of relief of bronchoconstrictions in patients with acute 
asthma when they are given either combined nebulized lignocaine & salbutamol or 
salbutamol only. 
3.1.2 To document the side effects of combined nebulized lignocaine and salbutamol. 
3.2 SPECIFIC OBJECTIVES 
3.2.1 To assess the difference of bronchoconstriction relief between patients nebulized 
with combination of lignocaine with salbutamol and salbutamol alone using the peak 
flowmeter. 
3.2.2 Other clinical improvements will be assessed by observing the difference of blood 
pressure, pulse rate, oxygen saturation level and respiration rate during the treatment. 
3.2.3 To document the side effects of combined nebulized lignocaine and salbutamoI. 
4. METHODOLOGY 
4.1 RESEARCH DESIGN (Figure 4.1) 
A prospective randomized controlled single blinded trial was conducted on 
patients whom presented themselves to the emergency department and has been 
categorized as mild and moderate asthma. 
4.1.1 VENUE 
This study was conducted at the Department Of Emergency Medicine, Hospital 
Universiti Sains Malaysia from September 2005 to February 2006. 
4.1.2 TIME FRAME 
This study was conducted from September 2005 to February 2006. 
4.1.3 APPROVAL 
This study was presented and subsequently approved by the Research and Ethical 
Committee, Pusat Pengajian Sains Perubatan, Universiti Sains Malaysia, Kubang Kerian, 
Kelantan. 
Patients that meets inclusion and 
exclusion criteria 
PEFR (Peak Expiratory Flow Rate) 









-Blood Pressure -Blood Pressure 
-Pulse Rate -Pulse Rate 
-Oxygen Saturation -Oxygen Saturation 
-Respiratory Rate -Respiratory Rate 
(to be taken 0,15 & 30mins) (taken at 0,15 & 30mins) 
Data Collect~lysed and differences of bronclioconstriction relief in the 2 
groups of patients will show the effectiveness of Lignocaine to be combined with 
Salbutamol in nebulized fonn for the treatment of acute asthma. 
Figure 4.1 Conceptual Framework 
